Navigation Links
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
Date:10/28/2009

ope.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to announce the completion of enrolment ahead of schedule for TB-402. We believe that based on its novel profile, TB-402 could be an important new entrant into the anticoagulant therapy market. Given the size of commercial opportunity for TB-402 and the sales reach that will be needed to engage with all of the potential prescribers of TB-402, it is our intention to seek a partner to undertake the later stage development and commercialisation of this exciting new agent. We very much look forward to announcing the results from this study in Q2 next year."

Svein Mathisen, CEO of BioInvent, also commented, "At BioInvent, we are proud to have maintained excellent momentum in the Phase II study of TB-402, which is on track to be completed ahead of schedule. We look forward to announcing the results of the study in Q2 next year. Our expectation is that the ongoing clinical development will underpin the product profile as a safe and effective long acting new anticoagulant."

About Deep Vein Thrombosis (DVT)

DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the U.S. alone, more than 600,000 patients are treated for venous thromboembolisms such as DVT or pulmonary embolism (PE) each year.[1] Moreover, DVT and PE together may be responsible for more than 100,000 deaths in the U.S. each year.[2]

It is estimated that by 2015, 1.4 million patients will undergo knee replacement and 600,000 patients will undergo hip replacement in the U.S. if current trends persist.[3] Patients undergoing hip replacement or knee surgery are particularly at risk of developing DVT and all patients are therefore treated with anticoagulants prophylactically in order to reduce the risks of blood clots. The annual sales of anticoagulants
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
2. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
3. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
4. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
5. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
6. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
7. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
8. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
9. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
10. Delcath Systems, Inc. Completes Phase III Study Enrollment
11. Abbott Completes Visiogen Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Decision Resources Group finds that ... Memphis health system and hospital sector ... with rivals Methodist Le Bonheur Healthcare and Baptist Memorial ... coordinate patient care. In addition, a national contract recently ... health plan enrollment in the Memphis ...
(Date:8/27/2014)... , Aug. 27, 2014 ISPE , ... it has released a preview of its Drug ... industry avoid drug shortages and maintain a robust and ... The Plan, a first for the industry, was ... industry members and describes how industry can best prevent ...
(Date:8/27/2014)... Conn. , Aug. 27, 2014 Pulse ... Record (EHR) , Practice Management , and Revenue ... little known business practices performed by some RCM vendors, at ... Philadelphia, PA on September 19-20, 2014.  ... Systems will return in September with a new session encouraging ...
Breaking Medicine Technology:Memphis-area Health Systems Turn Attention to Clinical Integration 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 3ISPE Releases First Look at its Plan to Prevent Drug Shortages 4Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 4
(Date:8/27/2014)... 27, 2014 BESLER Consulting , ... services for hospitals, is pleased to announce that it ... of America’s Fastest-Growing Companies. The list represents the most ... independent entrepreneurs. , "It's been an exciting year ... included in this year's Inc. 5000 list,” said Jonathan ...
(Date:8/27/2014)... designed to help regulate the blood,s iron supply shows promise ... to results from the first human study of ... , the Journal of the American Society of Hematology ... blood cells are in short supply or do not function ... get enough oxygen, since there are fewer red blood cells ...
(Date:8/27/2014)... State University,s Center for Leadership in Disability (CLD) ... Maternal and Child Health Bureau of the Health ... the Autism Plan for Georgia, aimed at improving ... disorder. , In preparing for this project, CLD ... key stakeholders from across Georgia. The resulting plan ...
(Date:8/27/2014)... Cash House 's contributions to Horizons ... upkeep of the shelter including new initiatives and a wide ... the lives of each youth who walk through their door. ... for youth ages 16-25. Not only does Horizons operate as ... for the youth who come through their doors. Horizons has ...
(Date:8/27/2014)... Houston, TX (PRWEB) August 27, 2014 ... The reality is that depression has a mortality ... those with bi-polar disorder is slightly less, though it's ... of roughly 7%. In order to properly treat ... schizophrenia, and bi-polar, medication must be taken as directed. ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:Drug represents first potential treatment for common anemia 2Health News:Cash House a Major Supporter of Horizons for Youth 2Health News:Cash House a Major Supporter of Horizons for Youth 3Health News:MedicationDiscountCard.com now Makes Brintellix and Mental Illness Medications More Affordable with Discount Cards 2
... study, there is a connection between certain bacteria in ... of using probiotics to treat autism.// ... this study. Though the results are very preliminary, he ... propose any link between autism and childhood vaccinations. ...
... of medical tourism has created new vistas, enabling a ... world.// In the race for being the best in ... the industry’s powerful trident - Pharmaceutical Industry, Doctors and ... well as diseases”, said Karl Marx, and what better ...
... from Spain are not too comfortable with the outcome of ... grace//, could carry a risk of formation of fatal blood ... 2000 as an upgraded version of bare-metal stents. ... have the drug-lined versions of the stents, which are designed ...
... Attention Deficit Hyperactivity Disorder (ADHD) cannot sit calmly at ... health professionals and parents are familiar with the symptoms, ... topic. ,The FDA has given instructions that ... should put up warnings about the possible side effects ...
... James, the British chairman of the International Obesity Task ... the obesity epidemic in poor countries. ,"The ... which subsidize and distort the market to make fats ... James said at the 10th International Obesity Congress in ...
... 150th anniversary celebrations of Madras University, his alma mater ... institutions in India. ,Speaking on the occasion, ... "Good teaching emanates from research. Any university is judged ... academics here. ,He opened a virtual university ...
Cached Medicine News:Health News:Probiotics – a probable treatment for Autis 2Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 2Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 3Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 4Health News:Alternative therapies for ADHD 2Health News:Alternative therapies for ADHD 3Health News:President Launches Madras University's 150th Year Celebrations 2
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
The VISULAS 532s combines ease of use, efficiency and safety to provide ophthalmologists with an overall system sharply focused on their requirements. ,The VISULAS 532s is a laser of many talent...
Medicine Products: